SubHero Banner

Sublocade (buprenorphine, extended-release) – New drug approval

November 30, 2017 – The FDA announced the approval of Indivior’s Sublocade (buprenorphine, extended-release) injection, for the treatment of moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of seven days.

Download PDF